Dr Adam Januszewski

🫁 Izalontamab brengitecan in actionable NSCLC. Phase Ib iza-bren showed activity across actionable NSCLC alterations beyond classical EGFR mutations: • ORR 39.7%, DCR 85.9%, median PFS 7.0 mo • EGFR exon20ins/nonclassical EGFR: ORR 69.2%, PFS 10.5 mo • HER2-mutant: ORR 52.9%, PFS 7.5 mo Relevant hematologic toxicity, but manageable safety profile overall. 📖 @JCO_ASCO DOI 👉🏻 doi.org/10.1200/JCO-25… #CánCare #NSCLC #EGFR #HER2 #ADC #targetedtherapy

Pleased that our case report on the rarely described EUS-guided transoesophageal pericardiocentesis for NSCLC posterior pericardial effusion has been published in Cardio-Oncology: rdcu.be/fgqPT @AdamJanuszewski @medicine98 @tb_doc @dr_manisty

🚨 Check out this new report discussing how can we provide fairer access to cancer treatments in collaboration with @macmillancancer ⬇️ publicpolicyprojects.com/no-patient-lef…

Final session: AI in Thoracic Oncology chaired by @AdamJanuszewski & @_johnedwards. “What does it all mean?” – grounding AI in clinical reality with Anita Grigoriadis. Enhancing radiology through AI – Rebecca Wray outlining practical applications. AI in pathological diagnosis – Mehrdad Rakaee exploring accuracy and augmentation. Clinical decision support with @PrelajArsela – balancing algorithms with judgement. #BTOG26

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…

⏰ This week! We’re looking forward to welcoming you to #BTOG26 for world-class science, debate and collaboration in thoracic oncology. Below is a series of live-style tweets from across the three days of #BTOG26, aligned to the programme and using the available faculty X handles . (Sponsored symposia excluded as requested.) --- **WEDNESDAY** Good morning from Edinburgh! ☕️ Registration is open and #BTOG26 is officially underway at the EICC. A packed programme ahead – great to see so many colleagues reconnecting. Kicking off Session 1a: Immune Cell Engagers in the Therapeutics Symposium. @BaijalDr & Yvonne Summers chairing. First up: T-cell engagers with Gary Middleton. #BTOG26 “Can a vaccine prevent lung cancer?” – compelling and thought-provoking talk from @sarah_blagden. Prevention science moving fast. #BTOG26 Is TIL therapy realistic in lung cancer? Fiona Thistlethwaite exploring promise vs practicality. A nuanced discussion on patient selection and logistics. #BTOG26 Managing CRS and ICANS – new toxicities, new challenges. Important clinical insights from Jane Robertson. #BTOG26 Over in Radiotherapy: single fraction SBRT for early-stage disease with @crispinhiley. Precision, pragmatism and pushing boundaries. #BTOG26 Cardio-oncology in radical RT – multidisciplinary perspectives from @finn_corinne and @sohaibnazir. Protecting the heart while treating the lung. #BTOG26 Diagnostics Symposium tackling incidental screening findings with Anna Bibby and radiology challenges with Annette Johnstone. Practical takeaways for MDTs. #BTOG26 Lunch & exhibition time 🍽️ Fuel, coffee and lively conversations across the stands. Edinburgh sunshine making a cameo appearance. #BTOG26 Afternoon Therapeutics: SACT in CNS disease chaired by @profsiahmed. Immunotherapy in CNS mets from @HendriksLizza – evolving data, real-world implications. #BTOG26 Targeted therapies in CNS disease – international perspective from Natasha Leighl. Clear message: biology matters. #BTOG26 Antibodies and ADCs with @Tony_Calles – mechanisms, momentum and where this fits in practice. #BTOG26 Diagnostics focus on mesothelioma: biomarkers & TNM9 staging from @SelinaTsim. Staging evolves as science does. #BTOG26 National mesothelioma MDTs – improving care or de-skilling teams? Provocative and practical from @preid80. #BTOG26 Opening Session chaired by @tnewsomdavis. NLCA State of the Nation 2026 from @LungConsultant – data driving accountability and improvement. #BTOG26 BTS update from @Nickmaskell1 and UKLCC update from @rintoul_robert. Collaboration across societies remains essential. #BTOG26 IASLC update from @HwakeleeMD – global perspective, shared challenges, shared ambition. #BTOG26 Posters & Welcome Reception now underway 🥂 Fantastic energy in the hall – innovation, debate and plenty of networking. #BTOG26 --- **THURSDAY** Early start for the #BTOG26 5K Fun Run 🏃‍♂️🏃‍♀️ Thoracic oncology meets Scottish pavements. Well done to all who took part! Session 4: Lung Cancer Research – Make the UK Great Again. Chaired by Samantha Cox & David Meek. UK research infrastructure update from Philippa Corrie – opportunities ahead. #BTOG26 Learning how to succeed (and fail) in trials with @ekslim. Honest reflections and invaluable lessons for investigators. #BTOG26 Global research – can the UK compete? Strategic overview from Gregory Lubiniecki. #BTOG26 Keynote: “The Perioperative Revolution in NSCLC” with @HwakeleeMD. Where we are and where we’re heading – practice-changing landscape. #BTOG26 Joint BTOG/APP Plenary on Stage III NSCLC chaired by David Snead & @fifimcdrmh. Borderline resectable disease discussion from @AndrearicFili. #BTOG26 NSCLC unsuitable for concurrent CRT – thoughtful insights from @gerryhanna. Complex patients, complex decisions. #BTOG26 Career Development Session for Trainees with @DrSanjayPopat, @finn_corinne, Sinan Eccles & Anna Bibby. Honest advice, open Q&A, standing room only. #BTOG26 BTOG/SCTS Joint Plenary: resectability & operability with @sharkeya and @amancoonar. Surgical boundaries continue to shift. #BTOG26 James Lind Alliance results presented by Babu Naidu – patient priorities shaping research agendas. #BTOG26 APP session: spread through adjacent airspaces – diagnostic relevance from Jan von der Thüsen. Detailed pathology discussion. #BTOG26 Refreshments break ☕️ Strong coffee, stronger opinions on optimal resection margins. #BTOG26 Poster Oral Presentations begin. AI detection on GP chest X-rays presented by @axd828 – technology meeting frontline care. #BTOG26 LCINS clinicopathological characteristics presented by Alexandra Holdich – important data for never smokers. #BTOG26 Congratulations to our #BTOG26 award winners – celebrating excellence across nursing, medicine and research. 👏 Conference Dinner at the National Museum of Scotland tonight ✨ Black tie, historic surroundings and a chance to unwind after two full days. --- **FRIDAY** Final day of #BTOG26 – coffee in hand and straight into Session 9: State of the Union – EBUS in the UK 2026. BTS Pilot Audit results presented by @emmalodowd. Transparent benchmarking and quality improvement in action. #BTOG26 Quality indicators and standards for EBUS from @DanSteinfort. Defining excellence in interventional bronchoscopy. #BTOG26 Future of interventional bronchoscopy with @ricky_thakrar – innovation balanced with safety and training. #BTOG26 Session 10: UK Academic Trial Landscape chaired by @DrSanjayPopat & @fblackhall. BTOG Research Group update from @DrSanjayPopat. #BTOG26 EORTC update from @MarianaBrandao0 – strengthening European collaboration. #BTOG26 CONCORDE update from @AlastairGreyst2 and THROMBO-STOP from Gary Middleton. UK-led trials with global impact. #BTOG26 Parallel Nurses Joint Session with @mcadam_julia & Paula Shepherd – Lung iAct study update from Christopher Dodd and Bing Smith. #BTOG26 Final session: AI in Thoracic Oncology chaired by @AdamJanuszewski & @_johnedwards. “What does it all mean?” – grounding AI in clinical reality with Anita Grigoriadis. #BTOG26 Enhancing radiology through AI – Rebecca Wray outlining practical applications. #BTOG26 AI in pathological diagnosis – Mehrdad Rakaee exploring accuracy and augmentation. #BTOG26 Clinical decision support with @PrelajArsela – balancing algorithms with judgement. #BTOG26 And that’s a wrap. Three days of science, collaboration and community. Thank you to everyone who joined us in Edinburgh. Safe travels – see you next year. #BTOG26 🔗 btog.org/24th-btog-annu… #LCSM #lungcancer

🚨The first results of our survey of oncologists, CNSs and dermatologists on skin toxicity management for EGFR mutant lung cancer patients ⬇️ Thanks to all who participated sciencedirect.com/science/articl… Come and see our poster @BTOGORG #BTOG26

Check our publication: Characterizing Risk Factors &Outcomes in Patients With Unresectable, StIII NSCLC Who Do Not Complete or Who Experience Progression During/Within 42 Days of, Concurrent Chemorad: The POSITION Study ⬇️ clinical-lung-cancer.com/article/S1525-…

Patients who are considered surgical candidates for mesothelioma have the best outcomes overall. (Healthy, lowest burden of disease, epithelial) And they have similarly good outcomes even if they decline a recommended meso operation. Coming in the print @annalsthorsurg soon:

Alice Roberts: Our Hospital Through Time 🏥 - Wednesday at 8pm ⁦@channel5_tv⁩

Important data in IO era. Should have a low threshold to stop pemetrexed maintenance for pts with stable or responding advanced lung adeno carcinoma. #lcsm

Check out this real world (England) data series of the impact of maintenance pemetrexed in 1st line NSCLC Median OS of 18.6 mo vs 19.5 Mo (not significant) with or without maintenance pemetrexed in 1000 pt case series: sciencedirect.com/science/articl…

Our #BTOG26 Annual Conference will close with a not-to-be-missed session on #AI in #ThoracicOncology, chaired by @AdamJanuszewski and @_johnedwards , with sessions titled: > What Does It All Mean? What You Need To Know About AI > Enhancing Radiology Through AI > AI in Pathological Diagnosis of Lung Cancer > AI Support in Clinical Decision Making btog.org/24th-btog-annu…

MDT Bridge just presented at #ESMO25 ➡️MDT-BRIDGE is 1st study to prospectively test neoadjuv IO+CT in patients with borderline resectable NSCLC ➡️95.2% of pts had either surgery or ChemoRT ➡️85.7% of pts had definitive resection ➡️Further follow-up is needed

Great to be in Berlin for @myESMO annual conference. Looks like some interesting data in lung cancer to come. #ESMO25 Behind the pics ⬇️

Join me at this @TheKingsFund roundtable webinar with Q&A discussing the implications of the 10 year health plan for cancer care with Prof Sir Mike Richards Leanne Graham Dr Urmi Shukla Sarah Woolnough Starts at 13:00 today. Sign up here ⬇️ #KFOnline kingsfund.org.uk/events/deliver…

Real world outcomes with neoadjuvant osimertinib and/or chemotherapy in EGFR NSCLC @LungCaJournal from Dr. @ChaftJamie. Noted 17% pCR with osimertinib (none with chemotherapy), MPR 44% osimertinib, 0% chemo, 10% osimertinib + chemo. lungcancerjournal.info/article/S0169-…

Join us for this @TheKingsFund online panel with S Woolnough Prof Sir M Richards CBE L Pero MBE Dr U Shukla Discussing what the NHS 10 year plan means for people living with cancer & how can ambition turn into action 16/Oct/25 @ 13:00-14:00 #KFOnline kingsfund.org.uk/events/deliver…

❗️Delighted to announce new partership between @BTOG & @IASLC ❗️ If you are a BTOG member, you get 30% off IASLC membership Even more reason to be a member of both organisations 🤗

BTOG Welcomes New Trainees to the Steering Committee: Oncology Trainee Representative from July 2025 Dr Kishen Patel Clinical Research Fellow / Clinical Oncology Registrar University College London Dr Paolo Davide d'Arienzo CRUK Clinical Research Training Fellow, RAS lab, The University of Manchester Medical Oncology Registrar, Northwest/South London Deanery Respiratory Trainee Representative from July 2025 Dr Michiala Cafferkey ST5 Respiratory NHS Lothian, Scotland Dr Tanya Patrick Clinical Research Fellow and Respiratory Registrar University College London and South Thames Deanery BTOG is very grateful to our out-going trainee representatives who have now progressed to consultant roles – we wish them every success. They have been in place since May 2022, and they will continue for a cross-over period to induct the new trainees. Gerard Walls, Consultant in Clinical Oncology & Honorary Research Fellow, Cancer Centre Belfast City Hospital and Queen’s University Belfast and Anand Sundaralingam, Consultant in Respiratory and General Medicine, Charing Cross Hospital/Imperial College Healthcare NHS Trust